{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-228131","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.136251+00:00","generated_at":"2026-06-11T00:04:47.036229+00:00","sec_items":["2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Mirum acquires Travere's bile acid products Cholbam and Chenodal for $210M upfront plus $235M milestones","bullets":["Completed asset purchase of Cholbam and Chenodal from Travere for $210M cash at closing, with up to $235M in sales-based milestone payments.","Funded acquisition via $210M PIPE at $26.25/share from investors including Frazier Life Sciences, Avidity Partners, BVF Partners.","Products treat rare liver diseases: bile acid synthesis disorders, peroxisomal disorders; Chenodal in Phase 3 for cerebrotendinous xanthomatosis (CTX).","Travere received $210M upfront and is eligible for additional milestones; Mirum expects near-term label expansion opportunity for CTX.","Financial statements for the acquired business to be filed as an amendment to this 8-K within 71 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-228131","json":"https://secwatch.observer/filing/0001193125-23-228131.json","markdown":"https://secwatch.observer/filing/0001193125-23-228131.md","text":"https://secwatch.observer/filing/0001193125-23-228131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/0001193125-23-228131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/d522051d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:04:47.036229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"524d5f855d692cd850e5a04f7706e22919e5b6df","claim":"Mirum Pharmaceuticals, Inc. completed an acquisition involving Travere Therapeutics, Inc. for an upfront purchase price of $210,000,000 in cash (closed 2023-08-31).","evidence_excerpt":"(the “Purchase Agreement”), dated July 16, 2023, by and between the Company and Travere. Under the terms of the Purchase Agreement, the Company paid an upfront purchase price of $210,000,000 in cash to Travere at the Asset Purchase Closing using cash and cash equivalents from the Company’s balance sheet. The Company may pay Travere up to $235,000,000 after the Asset","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523228131/0001193125-23-228131-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Travere Therapeutics, Inc."},{"label":"Consideration","value":"an upfront purchase price of $210,000,000 in cash"},{"label":"Closing","value":"2023-08-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}